A High Throughput CD39 Assay for the Ectonucleotidase Based on the Transcreener Platform
Discover CD39 Inhibitors with the Transcreener AMP2 Assay
The Transcreener AMP² CD39 Assay directly measures AMP produced by ectonucleoside triphosphate diphosphohydrolase-1 (also known as ENTPD1, NTPDase1, Cluster of Differentiation 39 or CD39). By measuring the production of AMP researchers can effectively determine the activity of the CD39 enzyme. The assay provides a powerful tool to screen entire compound libraries for CD39 modulators to help find new therapeutics for diseases such as cancer.
CD39 is an Important Messenger for Purinergic Signalling
Ectonucleotidases are plasma membrane-bound enzymes with externally oriented active sites that metabolize nucleotides to nucleosides and are crucial for maintaining immune homeostasis. CD39, hydrolyzes ATP and ADP to AMP. AMP can further be processed to adenosine leading to a significant impact on many disease states. Recent studies have shown a key role for adenosine in immunosuppression in the tumor microenvironment, and ectonucleotidases are emerging as promising immuno-oncology targets.
Direct Detection of AMP to Measure CD39 Enzymatic Activity
Recent Posts
New Publication by the Scientists at BellBrook Labs – Development of a High-Throughput Assay to Identify Inhibitors of ENPP1
Using a Universal GMP Assay for PDE Research
ST6GAL1 Drug Discovery to Combat Cancer
Helping Fight Ovarian Cancer with ST3GAL1 Inhibitors
ENPP1 Inhibitors, Assays, and Innate Immunity
